Targeting SHP2 reverses BRAF inhibitor tolerance in anaplastic thyroid carcinoma

CONCLUSION: The SHP2 inhibitor SHP099 can effectively reverse the drug resistance of dabrafenib through inhibiting the reactivated RAS signaling pathway in anaplastic thyroid cancer.The combination of dabrafenib with SHP2 inhibitor has shown significant tumor suppressive effects for dabrafenib-resistant cells and it may be a new therapeutic strategy with longer lasting therapeutic benefits.PMID:36786145 | DOI:10.2174/1871520623666230214093122
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research